Inherited predisposition to multiple myeloma

Therapeutic Advances in Hematology

Volumn 4, Issue 4, 2013, Pages 291-297

  Koura, Divya T ^a   Langston, Amelia A ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

autoantigens genetics; genetic predisposition to disease; monoclonal gammopathy of undetermined significance genetics; multiple myeloma epidemiology; multiple myeloma genetics; paraproteins genetics; phosphorylation physiology; risk factors; Waldenstr m macroglobulinemia genetics

Indexed keywords

LEUKOCYTE ANTIGEN; PARAPROTEIN; PP 7 PROTEIN; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ANTIGENICITY; AUTOSOMAL DOMINANT INHERITANCE; CANCER INCIDENCE; CANCER RISK; CHROMOSOME VARIANT; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HIGH RISK POPULATION; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RACE DIFFERENCE; REVIEW;

EID: 84993768045     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713485375     Document Type: Article

References (59)

1. Alexander D. Mink P. Adami H. Cole P. Mandel J. Oken M. et al. (2007) Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120(Suppl 12): 40–61.
2. Alexander L. Benninghoff D. (1965) Familial multiple myeloma. J Natl Med Assoc 57: 471–475.
3. Amos C. Wu X. Broderick P. Gorlov I. Gu J. Eisen T. et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40: 616–622.
4. Amundadottir L. Kraft P. Stolzenberg-Solomon R. Fuchs C. Petersen G. Arslan A. et al. (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41: 986–990.
5. Amundadottir L. Sulem P. Gudmundsson J. Helgason A. Baker A. Agnarsson B. et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652–658.
6. Bodmer W. Bailey C. Bodmer J. Bussey H. Ellis A. Gorman P. et al. (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328: 614–616.
7. Bourguet C. Grufferman S. Delzell E. de Long E. Cohen H. (1985) Multiple myeloma and family history of cancer. A case-control study. Cancer 56: 2133–2139.
8. Broderick P. Chubb D. Johnson D. Weinhold N. Forsti A. Lloyd A. et al. (2012) Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 44: 58–61.
9. Brown L. Linet M. Greenberg R. Silverman D. Hayes R. Swanson G. et al. (1999) Multiple myeloma and family history of cancer among blacks and whites in the US Cancer 85: 2385–2390.
10. Campa D. Martino A. Sainz J. Buda G. Jamroziak K. Weinhold N. et al. (2012) Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. Br J Haematol 157: 331–338.
11. Cannon-Albright L. Goldgar D. Meyer L. Lewis C. Anderson D. Fountain J. et al. (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258: 1148–1152.
12. Chung C. Chanock S. (2011) Current status of genome-wide association studies in cancer. Hum Genet 130: 59–78.
13. Crowther-Swanepoel D. Broderick P. Di Bernardo M. Dobbins S. Torres M. Mansouri M. et al. (2010) Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 42: 132–136.
14. Di Bernardo M. Crowther-Swanepoel D. Broderick P. Webb E. Sellick G. Wild R. et al. (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40: 1204–1210.
15. Dilworth D. Liu L. Stewart A. Berenson J. Lassam N. Hogg D. (2000) Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 95: 1869–1871.
16. Eeles R. Kote-Jarai Z. Giles G. Olama A. Guy M. Jugurnauth S. et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316–321.
17. Eriksson M. Hallberg B. (1992) Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 3: 63–67.
18. Ferlay J. Shin H. Bray F. Forman D. Mathers C. Parkin D. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
19. Geschickter C. Copeland M. (1928) Multiple myeloma. Arch Surg 16: 807–863.
20. Grass S. Iida S. Wikowicz A. Preuss K. Inagaki A. Shimizu K. et al. (2011 a) Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma. Cancer Sci 102: 565–568.
21. Grass S. Preuss K. Ahlgrimm M. Fadle N. Regitz E. Pfoehler C. et al. (2009) Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol 10: 950–956.
22. Grass S. Preuss K. Thome S. Weisenburger D. Witt V. Lynch J. et al. (2011 b) Paraproteins of familial MGUS / multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood 118: 635–637.
23. Grass S. Preuss K. Wikowicz A. Fadle N. Regitz E. Held G. et al. (2011 c) New Insights in the Pathogenesis of MGUS, multiple myeloma (MM) and Waldenström's Mmcroglobulinemia (WM): chronic antigenic stimulation by autoantigenic targets of paraproteins is mediated by CD4+ t-cells. Blood 118: 472.
24. Grass S. Preuss K. Wikowicz A. Terpos E. Ziepert M. Nikolaus D. et al. (2011 d) Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood 117: 2918–2923.
25. Gudmundsson J. Sulem P. Rafnar T. Bergthorsson J. Manolescu A. Gudbjartsson D. (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 40: 281–283.
26. Hall J. Lee M. Newman B. Morrow J. Anderson L. Huey B. et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684–1689.
27. Howlader N. Noone A. Krapcho M. Neyman N. Aminou R. Altekruse S. et al. (eds) (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethseda, MD: National Cancer Institute.
28. Huang A. Ho C. Ponzielli R. Barsyte-Lovejoy D. Bouffet E. Picard D. et al. (2005) Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res 65: 5607–5619.
29. Jain M. Ascensao J. Schechter G. (2009) Familial myeloma and monoclonal gammopathy: a report of eight African American families. Am J Hematol 84: 34–38.
30. Kiemeney L. Grotenhuis A. Vermeulen S. Wu X. (2009) Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol 19: 540–546.
31. Kristinsson S. Bjorkholm M. Goldin L. Blimark C. Mellqvist U. Wahlin A. et al. (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125: 2147–2150.
32. Kyle R. Rajkumar S. (2004) Multiple myeloma. N Engl J Med 351: 1860–1873.
33. Kyle R. Therneau T. Rajkumar S. Larson D. Plevak M. Offord J. et al. (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354: 1362–1369.
34. Leech S. Brian C. Elston R. Rainey J. Bickers J. Pelias M. (1983) Genetic studies in multiple Myeloma. Cancer 51: 1408–1411.
35. Lindblom A. Tannergard P. Werelius B. Nordenskjold M. (1993) Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 5: 279–282.
36. Lynch H. Watson P. Tarantolo S. Wiernik P. Quinn-Laquer B. Isgur Bergsagel K. et al. (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23: 685–693.
37. Maertens G. Cherepanov P. Engelman A. (2006) Transcriptional co-activator p 75 binds and tethers the Myc-interacting protein JPO 2 to chromatin. J Cell Sci 119: 2563–2571.
38. Mandema E. Wildervanck L. (1954) [Kahler's disease (multiple myeloma) in two sisters]. J Genet Hum 3: 170–175.
39. Martino A. Campa D. Jamroziak K. Reis R. Sainz J. Buda G. et al. (2012) Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. Br J Haematol 158: 805–809.
40. Mason D. Cullen P. (1975) HL-A antigen frequencies in myeloma. Tissue Antigens 5: 238–245.
41. McKay J. Hung R. Gaborieau V. Boffetta P. Chabrier A. Byrnes G. et al. (2008) Lung cancer susceptibility locus at 5p15.33. Nat Genet 40: 1404–1406.
42. Meyerding H. (1925) Multiple myeloma. Radiology 5: 132.
43. Monckton D. Caskey C. (1995) Unstable triplet repeat diseases. Circulation 91: 513–520.
44. Morgan G. Johnsen H. Goldschmidt H. Palumbo A. Cavo M. Sonneveld P. et al. (2012) Myeloma Genetics International Consortium. Leuk Lymphoma 53: 796–800.
45. Papaemmanuil E. Hosking F. Vijayakrishnan J. Price A. Olver B. Sheridan E. et al. (2009) Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 41: 1006–1010.
46. Parkin D. Bray F. Ferlay J. Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
47. Patel M. Wadee A. Galpin J. Gavalakis C. Fourie A. Kuschke R. et al. (2002) HLA class I and class II antigens associated with multiple myeloma in southern Africa. Clin Lab Haematol 24: 215–219.
48. Peltomaki P. Aaltonen L. Sistonen P. Pylkkanen L. Mecklin J. Jarvinen H. et al. (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260: 810–812.
49. Pottern L. Gart J. Nam J. Dunston G. Wilson J. Greenberg R. et al. (1992) HLA and multiple myeloma among black and white men: evidence of a genetic association. Cancer Epidemiol Biomarkers Prev 1: 177–182.
50. Preuss K. Pfreundschuh M. Ahlgrimm M. Fadle N. Regitz E. Murawski N. et al. (2009) A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer 125: 656–661.
51. Preuss K. Pfreundschuh M. Fadle N. Regitz E. Raudies S. Murwaski N. et al. (2011) Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP 2A. Blood 118: 3340–3346.
52. Shete S. Hosking F. Robertson L. Dobbins S. Sanson M. Malmer B. et al. (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41: 899–904.
53. Sobol H. Vey N. Sauvan R. Philip N. Noguchi T. Eisinger F. (2002) Re: familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 94: 461–462; author reply 463.
54. Struewing J. Hartge P. Wacholder S. Baker S. Berlin M. McAdams M. et al. (1997) The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 among Ashkenazi Jews. N Engl J Med 336: 1401–1408.
55. Trevino L. Yang W. French D. Hunger S. Carroll W. Devidas M. et al. (2009) Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 41: 1001–1005.
56. Wang Y. Broderick P. Webb E. Wu X. Vijayakrishnan J. Matakidou A. et al. (2008) Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 40: 1407–1409.
57. Wooster R. Neuhausen S. Mangion J. Quirk Y. Ford D. Collins N. et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088–2090.
58. Wrensch M. Jenkins R. Chang J. Yeh R. Xiao Y. Decker P. et al. (2009) Variants in the CDKN2B and RTEL 1 regions are associated with high-grade glioma susceptibility. Nat Genet 41: 905–908.
59. Wu X. Ye Y. Kiemeney L. Sulem P. Rafnar T. Matullo G. et al. (2009) Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41: 991–995.